A5066127598- Hepatitis C virus research
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- Liver Disease Diagnosis and Treatment
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- HIV/AIDS Research and Interventions
- Long-Term Effects of COVID-19
- Hepatitis B Virus Studies
- HIV-related health complications and treatments
- HIV, Drug Use, Sexual Risk
- Liver Disease and Transplantation
- SARS-CoV-2 detection and testing
- Infection Control and Ventilation
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Nuclear Structure and Function
- Sex work and related issues
- Heparin-Induced Thrombocytopenia and Thrombosis
- Pneumocystis jirovecii pneumonia detection and treatment
- COVID-19 Impact on Reproduction
- Dental Research and COVID-19
- Infection Control in Healthcare
- Tuberculosis Research and Epidemiology
- Sepsis Diagnosis and Treatment
Lillebaelt Hospital
2018-2025
Kolding Hospital
2012-2024
Stanford University
2022-2024
Australian National University
2022
National Institute of Allergy and Infectious Diseases
2022
Odense University Hospital
2005-2011
University of Southern Denmark
2010
Aarhus University Hospital
2007
Rigshospitalet
2001-2004
Office of Infectious Diseases
2002
Influence of age on the CD4 cell response to highly active antiretroviral therapy (HAART) was examined in 1956 patients (median age, 37.2 years) EuroSIDA study. Median initial count 192×106 cells/L, follow-up 31 months, and time maximum 20 months. Age groups were not different for baseline count, human immunodeficiency virus RNA load, or treatment history. increase, stratified by quartiles, differed during months 3–36 HAART (P=.023). Maximum increase from start group (P=.0003), as did...
The mortality in patients with persistent low CD4 count despite several years of HAART sustained viral suppression is poorly documented. We aimed to identify predictors for inadequate cell recovery and estimate but otherwise successful HAART.In a nationwide cohort HIV we identified all individuals who started before 1 January 2005 ≤ 200 cells/μL experienced three suppression. Patients were categorized according after the suppressed period (≤ cells/μL; immunological non-responders (INRs),...
Antiretroviral treatment with three nucleoside reverse transcriptase inhibitors (NRTIs) is widely used, but the combination of abacavir, didanosine and stavudine has never been investigated. We describe surprising consistent genotypic phenotypic outcome in patients failing this combination. As part a Danish multicentre study, 60 antiretroviral-naive were randomized to stavudine. Failure was defined as one HIV-1 RNA >400 copies/ml. Genotyping performed using TrueGene™ assay (Visible...
Background and aims Chronic hepatitis C virus (HCV) genotype 3 infection with advanced liver disease has emerged as the most challenging to treat. We retrospectively assessed treatment outcome of sofosbuvir (SOF) based regimes for HCV infections in a real life setting Scandinavia. Methods Consecutive patients chronic were enrolled at 16 centers Denmark, Sweden, Norway Finland. Patients who had received SOF containing regimen included. The fibrosis stage was evaluated by biopsy or transient...
Objective To describe the use of second line protease-inhibitor (PI) regimens across Europe and to determine factors associated with virological immunological response. Design Analysis data from 984 patients a median follow-up 21 months enrolled in EuroSIDA. Patients started their PI-containing regimen at least 16 weeks after starting first viral load > 1000 copies/ml. Methods Virological response was defined as < 500 copies/ml an increase 50 × 106/l or more CD4 lymphocyte count. Results The...
Human Immunodeficiency Virus (HIV) infection predisposes to tuberculosis (TB). We described incidence, risk factors and prognosis of TB in HIV-1 infected patients during pre (1995-1996), early (1997-1999), late Highly Active Antiretroviral Therapy (HAART) (2000-2007) periods. included from a population-based, multicenter, nationwide cohort. calculated incidence rates (IRs) mortality (MRs). Cox's regression analysis was used estimate for with HAART initiation as time updated variable....
Abstract Contaminated surfaces in clinics pose a pathogen transmission risk. Far ultraviolet-C light (UVC), with favorable safety profile for human exposure, has the potential continuous inactivation occupied clinical areas. This study demonstrated real-world bioburden reduction on surfaces, despite frequent contamination from routine use by staff and patients clinics.
Objective To investigate the skeletal muscle mitochondrial function in HIV-infected patients with lipdystrophy or elevated p-lactate levels. Design Eight HIV treated highly active antiretroviral therapy, lipodystrophy p-lactate, and eight healthy controls were exposed to incremental exercise until exhaustion. Methods Blood samples gas analysis performed at rest, during recovery. Oxygen consumption, workload blood lactate assessed. Before immediately after biopsies obtained, which citrate...
There is an increasing proportion of HIV-positive patients exposed to all licensed classes antiretrovirals, and the response salvage regimens may be poor. Among over 8500 in EuroSIDA, treated nucleosides, protease inhibitors (PIs) non-nucleoside reverse transcriptase inhibitor (NNRTI) increased from 0% 1996 47% 2001. Four-hundred-and-thirteen patients, who had failed virologically two highly active antiretroviral therapy (HAART) experienced three main drug classes, started a regimen at least...
Background Early identification of persons with undiagnosed HIV infection is an important health care issue. We examined associations between diseases diagnosed in hospitals and risk subsequent diagnosis. Methods In this population-based case control study, cases were incident Denmark 1 January 1995 June 2008. Risk-set sampling was used to identify 19 age- gender-matched population controls for each case, using the diagnosis date as index both controls. Prior hospital diagnoses obtained from...
Objectives: We describe factors associated with and barriers to initiation of Direct Acting Antiviral (DAA) treatment in patients chronic hepatitis C, who fulfill national fibrosis guidelines Denmark.Materials Methods: In this nationwide cohort study, we included C from The Danish Database for Hepatitis B (DANHEP) fulfilled criteria. Factors failure were determined by logistic regression analyses. Medical records reviewed criteria, but did not initiate DAA determine the cause.Results: 344...
AbstractAbstractBackground The goal of the C-Free-South project is to eliminate hepatitis C (HCV) in Region Southern Denmark (1.2 million inhabitants). One target group consists people with HCV who had received care but were lost follow-up. study aim was evaluate program efficacy locating these patients and getting them into care.Methods Patients contacted if they HCV-RNA positive age 18+ years, registered clinical database as November 1, 2019, no scheduled HCV-related appointment. They at...
Mette Vang Larsen*a, Lars Haukali Omlandb, Jan Gerstoftb, Birgit T. Røgec, Carsten Schade Larsend, Gitte Pedersene, Niels Obelb & Kronborgaa Department of Infectious Diseases, Copenhagen University Hospital, Hvidovreb Rigshospitalet, Copenhagenc Odense Odensed Aarhus Aarhuse Aalborg Aalborg, Denmark
Background and Aims The first standard of care in treatment chronic HCV genotype 1 infection involving directly acting antivirals was protease inhibitors telaprevir or boceprevir combined with pegylated-interferon ribavirin (triple therapy). Phase III studies include highly selected patients. Thus, response development viral resistance during triple therapy a routine clinical setting needs to be determined. aims this study were investigate outcome identify sequence variations after patients...
Objective To study the evolution of multi-drug-resistant HIV-1 in treatment-experienced patients receiving foscarnet (PFA) as part salvage therapy and to investigate virological consequences emerging mutations. Methods Genotypic phenotypic resistance tests were performed on plasma viruses from seven at baseline during treatment with PFA. The effects mutations suspected be associated PFA evaluated by site-directed mutagenesis wild-type or thymidine analogue (TAM)-carrying pNL4–3. Reversion...
Denmark has signed the WHO strategy to eliminate hepatitis C virus (HCV). In absence of a national for elimination, local action plan was developed in Region Southern (RSD). The aim is diagnose 90% HCV-infected persons and treat 80% those diagnosed by 2025. reviewing Danish data on HCV epidemiology drug use identify key populations screening, linkage care, treatment. Based available published from 2016, an estimated 3028 RSD were HCV-RNA positive (population prevalence 0.21%). Of these, 1002...
Enhancing treatment uptake for hepatitis C to achieve the elimination goals set by World Health Organization could be achieved reducing duration. The aim of this study was compare sustained virological response at week 12 (SVR12) after four weeks glecaprevir/pibrentasvir (GLE/PIB) + ribavirin compared eight GLE/PIB and estimate predictors SVR12 with through a multicenter open label randomized controlled trial. Patients were 2:1 (4 weeks:8 weeks) stratified genotype 3 naïve all genotypes...
Immunocompromised patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can have a longer duration of viral shedding and persistence symptoms. The optimal treatment strategy for these remains to be established. This case describes male in his late sixties follicular lymphoma persistent symptoms infection SARS-CoV-2 variant BA.2 who was treated remdesivir five times over period six months. clinical effect decreased time, further sequencing revealed the emergence...
Direct-acting antivirals (DAAs) have proven highly effective against chronic hepatitis C virus (HCV) infection. However, some patients experience treatment failure, associated with resistance-associated substitutions (RASs). Our aim was to investigate the complete viral coding sequence in treated DAAs identify RASs and effects of on population. We selected 22 HCV sustained virologic response (SVR) match 21 treatment-failure relation genotype, DAA regimen, liver cirrhosis previous experience....
New potent direct-acting antiviral (DAA) regimens against hepatitis C virus have been approved in recent years. However, information about the rate of adverse events (AEs) across different DAA is limited. We aimed to evaluate differences AEs and treatment efficacy patients with chronic (CHC), genotype (GT) 1 or 3, randomized two arms, correspondingly.We randomly assigned 96 a : ratio, for 12 weeks either paritaprevir/ombitasvir/ritonavir/dasabuvir/ribavirin (RBV) ledipasvir/sofosbuvir...
Background and aims To evaluate the ability of pretreatment liver stiffness measurements (pLSM) to predict hepatocellular carcinoma (HCC), incident decompensation all-cause mortality in chronic hepatitis C (CHC) patients who achieved sustained virological response (SVR) after treatment with direct-acting antivirals (DAAs). Methods 773 CHC SVR DAA no prior complications were identified retrospectively. Optimized cut-off 17.5 kPa for HCC was selected by maximum Youden’s index. Patients grouped...
We used foscarnet as induction therapy or maintenance in different dosing regimens seven severely immunocompromised multidrug-resistant HIV-1 patients. During the median decrease viral load was 1.8 log and increases CD4 cell counts ranging from zero to 136 cells/mm3were observed during therapy, suggesting that could be an option salvage patients with no treatment options left. Foscarnet is a pyrophosphate analogue inhibits several polymerases, including reverse transcriptase, presumably by...